Johnson & Johnson Agrees $5.5bn Talc Lawsuit Settlement
The company will pay an estimated sum to resolve tens of thousands of claims alleging its talc products caused cancer.
Trust 42Craft 55Hype 15How this was reported ▾
Only one named source (Erik Haas) with no independent verification.
How well corroborated and evidenced the reporting is. Higher is better.
Clear facts but lacks affected parties' voices or local angle.
Context, balance and separation of fact from comment. Higher is better.
Headline matches substance; no exaggerated language.
How far presentation runs ahead of substance. Lower is better.
1 source assessed · methodology
Johnson & Johnson has announced an estimated $5.5bn settlement to resolve tens of thousands of legal claims. These lawsuits allege that the company's talc-based baby powder and other products led to ovarian cancer. This agreement aims to conclude a contentious legal battle that has spanned a decade.
The proposed settlement encompasses approximately 76,000 claims, including those consolidated in a federal court in New Jersey and related state court cases. This represents nearly all outstanding talc-related claims against the company. Johnson & Johnson had previously settled the majority of cases alleging its talc contained asbestos and caused mesothelioma.
Sunseeker Holiday Homes enters administration
The Hull-based manufacturer, founded in 2019, has appointed administrators, putting 76 jobs at risk.
Company's Stance and Payment Schedule
Erik Haas, Johnson & Johnson's vice-president of litigation, stated that the company views the claims as "meritless" but is settling to achieve closure. He added that while confident in prevailing in further litigation, this resolution allows the company to focus on its mission. Johnson & Johnson anticipates paying $3bn in 2027, with additional payments in 2028. The final payout could exceed $5.5bn depending on claimant participation.
Chris Seeger, a lawyer representing about 2,500 clients with talc claims, helped negotiate the agreement. He indicated that the total payout could reach $7bn or more, as the settlement assigns specific values to qualifying ovarian cancer claims without capping the overall expenditure. Seeger expressed satisfaction, stating, "We got a fair settlement, and our clients are going to be happy with it."
Enfield Town Liveable Neighbourhood scheme paused pending review
Transport for London funding for next phase is on hold as council re-evaluates project elements.
Background to the Settlement
This settlement follows a series of legal victories for Johnson & Johnson, including successful trials, disqualification of some plaintiffs' lawyers, and rulings against expert witnesses. A federal judge recently cast doubt on individual plaintiffs' ability to prove talc specifically caused their ovarian cancer. The company has consistently denied that its talc products cause cancer, asserting their safety and absence of asbestos.
Johnson & Johnson ceased selling talc-based baby powder in the US in 2020, transitioning to a cornstarch-based product. Litigation had resumed in March 2025 after being paused for over three years during unsuccessful attempts by the company to settle cases through bankruptcy filings via a subsidiary. These bankruptcy efforts were ultimately dismissed.
Prior to these bankruptcy attempts, Johnson & Johnson had a mixed record in talc trials, including a multi-billion dollar verdict favouring 22 women who claimed baby powder caused their ovarian cancer. Some verdicts were later reduced on appeal. The current agreement exclusively addresses existing claims and does not cover future lawsuits.
Finalisation of the Deal
For the settlement to become final, it must be approved by 95% of the ovarian cancer claimants involved in either state or federal court proceedings. Lawyers noted that the exclusion of future claims makes more funds available to current plaintiffs compared to previous bankruptcy proposals. Additionally, the payment schedule accelerates, with all claims expected to be settled within 18 months.
Questions this report answers
+How much will Johnson & Johnson pay in total?
Johnson & Johnson will pay an estimated $5.5bn to resolve around 76,000 lawsuits. The final payout could exceed this amount, potentially reaching $7bn or more, depending on claimant participation and assigned values for qualifying ovarian cancer claims.
+When will the payments be made?
Payments are scheduled for 2027 and 2028, with $3bn due in 2027 and additional payments in 2028. All claims are expected to be settled within 18 months once the agreement is finalised.
+Who does this settlement cover?
The settlement covers approximately 76,000 existing claims alleging that Johnson & Johnson's talc products caused ovarian cancer. It does not include future lawsuits or claims related to mesothelioma from asbestos.
+What happens next for the settlement?
The deal requires acceptance from 95% of ovarian cancer claimants to be finalised. If approved, payments will begin in 2027, with all claims resolved within 18 months.
Barnet Press News Desk
This article was written at the Barnet Press news desk from the reporting of the outlets listed below it. Drafting is done by a language model under human editorial supervision — there is no reporter behind this byline, and we would rather say so than invent one.
How stories are produced and scoredWho runs Barnet PressCorrections
Barnet conditions
Loading live conditions…
More Coverage in World
Sunseeker Holiday Homes enters administration
Enfield Town Liveable Neighbourhood scheme paused pending review
